Skip to main navigation

For Investors
News
Careers
Contact Us
COVID-19 Candidate Updates

About Us
- Our Team
- Our Partners
Our Pipeline
Science and Technology
Resources

About Us
- Our Team
- Our Partners
Our Pipeline
Science and Technology
Resources
For Investors
News
Careers
Contact Us
COVID-19 Candidate Updates

Press Releases & Statements

Investor Relations

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Year Category Keywords

Advanced Search

Search

Search Headlines Only

Category

From

To

Asset Types

Photos Video Audio Documents Events Standard

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate
- COVID-19
Jul 23, 2020
Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress
- COVID-19
Jul 20, 2020
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
- Corporate and Finance
Jul 7, 2020
Novavax Announces Updates to Leadership Team
- Corporate and Finance
Jul 2, 2020
Novavax Expands Executive Leadership and Announces Key Promotions
- Corporate and Finance
Jun 29, 2020
Novavax to Participate in H.C. Wainwright Fireside Chat Series
- Corporate and Finance
Jun 24, 2020
Novavax Announces Additions to Executive Leadership
- Corporate and Finance
Jun 17, 2020
Novavax Appoints Biotechnology Veteran David Mott to Board of Directors
- Corporate and Finance
Jun 16, 2020
Novavax to Raise $200 Million from Private Placement with RA Capital
- Corporate and Finance
Jun 15, 2020
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital
- COVID-19
Jun 8, 2020
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
- COVID-19
Jun 4, 2020
Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine
- Matrix-M™ Adjuvant
Jun 3, 2020
Novavax Expands Large-Scale Global Manufacturing Capacity
- Corporate and Finance
May 27, 2020
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
- COVID-19
May 25, 2020
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
- COVID-19
May 11, 2020
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
- COVID-19
May 11, 2020
Novavax Reports First Quarter 2020 Financial Results
- Corporate and Finance
May 11, 2020
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
- Corporate and Finance
May 6, 2020
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
- COVID-19
Apr 8, 2020
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
- Seasonal Influenza
Mar 24, 2020
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
- Partners
Mar 11, 2020
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
- Corporate and Finance
Mar 11, 2020
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
- COVID-19
Mar 10, 2020
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
- Corporate and Finance
Mar 5, 2020
Novavax Advances Development of Novel COVID-19 Vaccine
- COVID-19
Feb 26, 2020
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
- Seasonal Influenza
Feb 25, 2020
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
- Seasonal Influenza
Jan 15, 2020
Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference
- Corporate and Finance
Jan 9, 2020
Novavax Reports Third Quarter 2019 Financial Results
- Corporate and Finance
Nov 7, 2019
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019
- Corporate and Finance
Oct 31, 2019
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
- Seasonal Influenza
Oct 15, 2019
Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference
- Corporate and Finance
Sep 19, 2019
Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference
- Corporate and Finance
Sep 6, 2019
New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting
- RSV
Aug 12, 2019
Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting
- RSV
Aug 8, 2019
Novavax Reports Second Quarter 2019 Financial Results
- Corporate and Finance
Aug 7, 2019
Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu
- Seasonal Influenza
Aug 5, 2019
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019
- Corporate and Finance
Aug 1, 2019
Novavax and Catalent Announce Closing of Strategic Partnership
- Partners
Jul 31, 2019
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
- Partners
Jun 27, 2019
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
- Seasonal Influenza
Jun 27, 2019
Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
- RSV
Jun 10, 2019
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
- Seasonal Influenza
Jun 4, 2019
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
- Corporate and Finance
May 10, 2019
Novavax Announces Reverse Stock Split of Common Stock
- Corporate and Finance
May 8, 2019
Novavax Reports First Quarter 2019 Financial Results
- Corporate and Finance
May 2, 2019
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
- RSV
May 1, 2019
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
- Corporate and Finance
Apr 25, 2019
Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
- RSV
Apr 9, 2019
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
- Corporate and Finance
Mar 18, 2019
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019
- Corporate and Finance
Mar 11, 2019
Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
- RSV
Feb 28, 2019
Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults
- Seasonal Influenza
Jan 3, 2019
Novavax to Present at the 37th Annual J.P. Morgan Healthcare Conference
- Corporate and Finance
Jan 2, 2019
Novavax Announces Leadership Promotions
- Corporate and Finance
Dec 4, 2018
Novavax Expands Leadership with Several Key Management Promotions
- Corporate and Finance
Nov 12, 2018
Novavax Reports Third Quarter 2018 Financial Results
- Corporate and Finance
Nov 7, 2018
Novavax Appoints Rachel King to Board of Directors
- Corporate and Finance
Nov 1, 2018
Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2018
- Corporate and Finance
Nov 1, 2018
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
- RSV
Oct 2, 2018
Novavax to Present at Two Upcoming Investor Conferences
- Corporate and Finance
Sep 26, 2018
Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults
- Seasonal Influenza
Sep 25, 2018
Novavax to Participate at Two Upcoming Investor Conferences
- Corporate and Finance
Aug 28, 2018
Novavax Reports Second Quarter 2018 Financial Results
- Corporate and Finance
Aug 8, 2018
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018
- Corporate and Finance
Aug 1, 2018
New England Journal of Medicine Publishes Novavax’ NanoFlu Clinical Trial Data
- Seasonal Influenza
Jun 13, 2018
Novavax CEO to Discuss Future of Global Vaccine Business as Part of Panel of Industry Leaders at 2018 BIO International Convention
- Corporate and Finance
May 31, 2018
Novavax Reports First Quarter 2018 Financial Results
- Corporate and Finance
May 9, 2018
Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine
- RSV
May 7, 2018
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018
- Corporate and Finance
May 2, 2018
Novavax Announces Closing of Public Offering
- Corporate and Finance
Apr 16, 2018
Novavax Announces Proposed Public Offering of Common Stock
- Corporate and Finance
Apr 11, 2018
Novavax Prices Public Offering of Common Stock
- Corporate and Finance
Apr 11, 2018
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
- Seasonal Influenza
Apr 2, 2018
Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer
- Corporate and Finance
Mar 14, 2018
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
- Corporate and Finance
Mar 14, 2018
Novavax to Host Conference Call and Webcast to Provide Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
- Corporate and Finance
Mar 7, 2018
Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
- Seasonal Influenza
Feb 28, 2018
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
- RSV
Dec 18, 2017
Novavax to Present at the Stifel 2017 Healthcare Conference
- Corporate and Finance
Nov 8, 2017
Novavax Reports Third Quarter 2017 Financial Results
- Corporate and Finance
Nov 7, 2017
Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
- Corporate and Finance
Oct 31, 2017
Novavax Announces Leadership Change
- Corporate and Finance
Oct 13, 2017
Novavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults
- Seasonal Influenza
Sep 19, 2017
Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference
- Corporate and Finance
Sep 19, 2017
Novavax to Participate in the Citi 12th Annual Biotech Conference
- Corporate and Finance
Sep 5, 2017
Novavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine
- Seasonal Influenza
Aug 23, 2017
Novavax Reports Second Quarter 2017 Financial Results
- Corporate and Finance
Aug 8, 2017
Novavax to Host Conference Call to Discuss Second Quarter 2017 Financial Results on August 8, 2017
- Corporate and Finance
Aug 1, 2017
Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
- RSV
Jul 24, 2017
Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
- Corporate and Finance
Jul 21, 2017
Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
- RSV
Jul 17, 2017
Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine
- RSV
Jun 7, 2017
Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine
- Corporate and Finance
May 11, 2017
Novavax Reports First Quarter 2017 Financial Results
- Corporate and Finance
May 8, 2017
Novavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017
- Corporate and Finance
May 1, 2017
Novavax Reports Fourth Quarter and Year-End 2016 Financial Results
- Corporate and Finance
Feb 27, 2017
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2016 Financial Results on February 27, 2017
- Corporate and Finance
Feb 20, 2017
Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults
- RSV
Jan 19, 2017
Novavax to Present at the 35th Annual J.P. Morgan Healthcare Conference
- Corporate and Finance
Jan 5, 2017

Show 5 10 25 50 100 per page

«
1
2
3
»

Site - Shareholder Tools

Print Page
Email Alerts

For Investors
News

Contact Us
- 21 Firstfield Road
  Gaithersburg, MD 20878
  
  (240) 268-2000
Social
Site - Footer Social
- Privacy Policy | Terms and Conditions
  
  Pay Transparency Nondiscrimination Provision
  
  Purchase Order Terms and Conditions

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept